Insider Buying: CSL (ASX:CSL) Insider Buys A$27,734.93 in Stock

CSL Limited (ASX:CSL) insider Robert Cuthbertson purchased 183 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were bought at an average cost of A$151.56 per share, for a total transaction of A$27,734.93.

CSL Stock Performance

The company has a market cap of $77.43 billion, a PE ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.

CSL Dividend Announcement

The company also recently declared a Interim dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Wednesday, April 8th will be given a dividend of $1.837 per share. This represents a yield of 121.0%. The ex-dividend date of this dividend is Monday, March 9th. CSL’s payout ratio is 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.